Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fu-Jie Shen

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|May 9, 2006
[Application of Excel Visual Basic for efficiently complete statistic analysis]Xu-Hong Hou, Fu-Jie Shen, Jian-Hua Wang, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|November 24, 2004
[Epidemiology of communicable diseases in Huangpu District, Shanghai City, 1996--2002]Jian-jun Zhou, Fu-jie Shen, Juan-min Ren, et al.
BMC Bioinformatics|August 28, 2024
Prediction of mutation-induced protein stability changes based on the geometric representations learned by a self-supervised methodShan Shan Li, Zhao Ming Liu, Jiao Li, et al.
Science (New York, N.Y.)|September 26, 2024
Mutating a flexible region of the RSV F protein can stabilize the prefusion conformationYu Liang, Shuai Shao, Xin Yu Li, et al.
Biochemical and Biophysical Research Communications|May 22, 2026
Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccinesShuai Shao, Ze Yuan Dong, Zi Yao Kang, et al.
Elife|August 25, 2022
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variantsJing Zhang, Zi Bo Han, Yu Liang, et al.
Cell Discovery|February 16, 2022
Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2Yu Liang, Jing Zhang, Run Yu Yuan, et al.
Signal Transduction and Targeted Therapy|June 6, 2022
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trialNawal Al Kaabi, Yun Kai Yang, Jing Zhang, et al.
Signal Transduction and Targeted Therapy|January 3, 2023
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trialNawal Al Kaabi, Yun Kai Yang, Yu Liang, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|May 9, 2006
[Application of Excel Visual Basic for efficiently complete statistic analysis]Xu-Hong Hou, Fu-Jie Shen, Jian-Hua Wang, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|November 24, 2004
[Epidemiology of communicable diseases in Huangpu District, Shanghai City, 1996--2002]Jian-jun Zhou, Fu-jie Shen, Juan-min Ren, et al.
BMC Bioinformatics|August 28, 2024
Prediction of mutation-induced protein stability changes based on the geometric representations learned by a self-supervised methodShan Shan Li, Zhao Ming Liu, Jiao Li, et al.
Science (New York, N.Y.)|September 26, 2024
Mutating a flexible region of the RSV F protein can stabilize the prefusion conformationYu Liang, Shuai Shao, Xin Yu Li, et al.
Biochemical and Biophysical Research Communications|May 22, 2026
Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccinesShuai Shao, Ze Yuan Dong, Zi Yao Kang, et al.
Elife|August 25, 2022
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variantsJing Zhang, Zi Bo Han, Yu Liang, et al.
Cell Discovery|February 16, 2022
Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2Yu Liang, Jing Zhang, Run Yu Yuan, et al.
Signal Transduction and Targeted Therapy|June 6, 2022
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trialNawal Al Kaabi, Yun Kai Yang, Jing Zhang, et al.
Signal Transduction and Targeted Therapy|January 3, 2023
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trialNawal Al Kaabi, Yun Kai Yang, Yu Liang, et al.
Pageof 1